HEALTH
From Times Staff and Wire Reports
ImmunoGen to Slash Payroll: ImmunoGen Inc. said it will lay off 100 of its 180 employees, or about 60% of its work force, and cut senior management salaries 20% to reduce expenses. The Cambridge, Mass., biopharmaceutical developer also will suspend manufacturing and new product development to focus on continued development of its lead product, Oncolysin B, a drug in Phase III clinical testing that may prevent relapses in lymphoma patients.
